Back to Search Start Over

2- 18 F-Fluoroethanol Is a PET Reporter of Solid Tumor Perfusion.

Authors :
Wadsworth BJ
Pan J
Dude I
Colpo N
Bosiljcic M
Lin KS
Benard F
Bennewith KL
Source :
Journal of nuclear medicine : official publication, Society of Nuclear Medicine [J Nucl Med] 2017 May; Vol. 58 (5), pp. 815-820. Date of Electronic Publication: 2017 Jan 26.
Publication Year :
2017

Abstract

Solid tumor perfusion is a proven variable of interest for predicting cancer aggression and response to therapy. Current methods for noninvasively imaging tumor perfusion with PET are limited by restricted accessibility and short half-lives of perfusion radiotracers. This study presents 2- <superscript>18</superscript> F-fluoroethanol (2- <superscript>18</superscript> F-FEtOH) as a perfusion reporter that can distinguish between tumors of varying perfusion levels and can be applied to screening drugs that modify tumor perfusion. Methods: Uptake of 2- <superscript>18</superscript> F-FEtOH in 4T1 and 67NR murine mammary carcinoma tumors grown in mice was measured using ex vivo radiography as well as static and dynamic PET imaging. 2- <superscript>18</superscript> F-FEtOH uptake was directly compared with the <superscript>14</superscript> C-iodoantipyrine perfusion reporter, and the perfusion-modifying drugs nicotinamide, pentoxifylline, and hydralazine were used to manipulate tumor perfusion before 2- <superscript>18</superscript> F-FEtOH quantification. Results: Uptake of 2- <superscript>18</superscript> F-FEtOH in 4T1 and 67NR tumors was consistent with known perfusion differences within and between these tumors. 2- <superscript>18</superscript> F-FEtOH uptake corresponded well with <superscript>14</superscript> C-iodoantipyrine and reflected the tumor perfusion-modifying effects of each drug. Conclusion: 2- <superscript>18</superscript> F-FEtOH is a novel <superscript>18</superscript> F-based radiotracer for investigating tumor perfusion with PET imaging. Quantification of 2- <superscript>18</superscript> F-FEtOH uptake can be used to distinguish between tumors of varying perfusion and to screen the efficacy of blood flow-modifying drugs for use as adjuvants to existing cancer therapies.<br /> (© 2017 by the Society of Nuclear Medicine and Molecular Imaging.)

Details

Language :
English
ISSN :
1535-5667
Volume :
58
Issue :
5
Database :
MEDLINE
Journal :
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Publication Type :
Academic Journal
Accession number :
28126891
Full Text :
https://doi.org/10.2967/jnumed.116.183624